An observational study in Venous Thromboembolism, Pulmonary Thromboembolisms and Cancer, sponsored by Delos Clinical. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-01.
Sponsored by Delos Clinical · Observational
Cancer is the most important acquired risk factor of thromboembolisms. More than 20% of all episodes of venous thromboembolism (VT) or pulmonary thromboembolisms (PT) are cancer related. Cancer patients with VT or PT are treated with low molecular weight heparins (LMWH) during at least 3 months, but nowadays the duration of treatment is not accurately determined.
The D-Dimer determination has been used like recurrence predictors after LMWH treatment suspension, but in cancer patients the useful is limited. Phospholipid-dependent microparticles could been used like recurrence predictors in cancer patients and tailored the duration of LMWH treatment for each patient.
We are carrying out a study in Cancer-associated-thromboembolism patients in order to decide the suitable anticoagulation time. A set of exclusion criteria is being used to determine in which patients LMWH will be withdrawn. Patients are being followed after LMWH withdrawal until 6 months. Blood samples are being taken at baseline (LMWH withdrawal), 3 weeks and 3 months after. We will look for association between several biomarkers and venous thromboembolism recurrences.
738 studies on the registry are indexed under Pulmonary Embolism; 158 are open to participants now.
This study's enrollment of 352 is close to the median of 383 across 323 observational studies indexed under Pulmonary Embolism.
Browse Pulmonary Embolism studies →This is the only study on the registry with Delos Clinical as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Patient with diagnosis of cancer (any) and diagnosis of pulmonary thromboembolism (PT) or venous thromboembolism (VT) , in treatment with low molecular weight heparin (LMWH).
Exclusion Criteria:
Recurrence thromboembolisms
Venous thromboembolisms or Pulmonary thromboembolism recurrence after LMWH suppression
Time frame: 3 months
Recurrence thromboembolisms
Venous thromboembolisms or Pulmonary thromboembolism recurrence after LMWH suppression
Time frame: 6 months
Hemorrhagic events
Hemorrhagic events due to LMWH treatment
Time frame: 6 months
Thromboembolic event attributable death
Death related to embolic event
Time frame: 6 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.